Fritz Offner

17.4k total citations · 3 hit papers
236 papers, 6.1k citations indexed

About

Fritz Offner is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Fritz Offner has authored 236 papers receiving a total of 6.1k indexed citations (citations by other indexed papers that have themselves been cited), including 119 papers in Pathology and Forensic Medicine, 98 papers in Genetics and 84 papers in Oncology. Recurrent topics in Fritz Offner's work include Lymphoma Diagnosis and Treatment (118 papers), Chronic Lymphocytic Leukemia Research (94 papers) and CAR-T cell therapy research (42 papers). Fritz Offner is often cited by papers focused on Lymphoma Diagnosis and Treatment (118 papers), Chronic Lymphocytic Leukemia Research (94 papers) and CAR-T cell therapy research (42 papers). Fritz Offner collaborates with scholars based in Belgium, United States and United Kingdom. Fritz Offner's co-authors include Jan Philippé, Ann Janssens, Lucien Noens, Sofie Lust, Bertrand Coiffier, Michael Crump, Raoul Herbrecht, Dominique Benoît, Gregor Verhoef and Johan Decruyenaere and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Fritz Offner

226 papers receiving 6.0k citations

Hit Papers

Phase III Study to Evalua... 2009 2026 2014 2020 2009 2019 2022 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
    2009 485 citations Georg Heß, Gregor Verhoef et al. Journal of Clinical Oncology profile →
  2. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
    2019 312 citations Jan A. Burger, Paul M. Barr et al. profile →
  3. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia 
    2022 146 citations Paul M. Barr, Carolyn Owen et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Fritz Offner 2.7k 2.3k 2.0k 1.3k 1.1k 236 6.1k
Anders Österborg 2.5k 0.9× 2.2k 1.0× 2.7k 1.4× 1.5k 1.1× 3.2k 2.8× 204 7.5k
Diane F. Jelinek 3.1k 1.2× 2.8k 1.2× 3.9k 2.0× 3.6k 2.8× 4.4k 3.8× 205 10.8k
Adrian C. Newland 1.3k 0.5× 1.2k 0.5× 1.2k 0.6× 1.8k 1.4× 1.6k 1.4× 281 8.1k
W. Hunstein 1.3k 0.5× 1.9k 0.8× 1.5k 0.7× 1.1k 0.8× 1.4k 1.2× 194 5.2k
Andrew D. Clouston 1.3k 0.5× 2.4k 1.0× 378 0.2× 1.4k 1.1× 2.1k 1.9× 197 11.4k
Christian Récher 854 0.3× 1.9k 0.8× 1.8k 0.9× 4.4k 3.4× 1.0k 0.9× 299 9.1k
Norbert Ifrah 1.2k 0.4× 3.5k 1.5× 1.7k 0.9× 3.9k 3.0× 1.8k 1.6× 231 11.4k
Timothy G. Call 3.4k 1.3× 1.1k 0.5× 4.0k 2.0× 837 0.6× 2.2k 1.9× 221 5.8k
Tsutomu Nobori 478 0.2× 2.1k 0.9× 495 0.2× 2.9k 2.2× 819 0.7× 210 7.8k
Lothar Bergmann 798 0.3× 1.4k 0.6× 662 0.3× 2.1k 1.6× 1.0k 0.9× 182 4.8k

Countries citing papers authored by Fritz Offner

Since Specialization
Citations

This map shows the geographic impact of Fritz Offner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fritz Offner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fritz Offner more than expected).

Fields of papers citing papers by Fritz Offner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fritz Offner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fritz Offner. The network helps show where Fritz Offner may publish in the future.

Co-authorship network of co-authors of Fritz Offner

This figure shows the co-authorship network connecting the top 25 collaborators of Fritz Offner. A scholar is included among the top collaborators of Fritz Offner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fritz Offner. Fritz Offner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kater, Arnon P., Ann Janssens, Herbert Eradat, et al.. (2024). SINGLE-AGENT EPCORITAMAB LEADS TO DEEP RESPONSES IN PATIENTS (PTS) WITH RICHTER’S TRANSFORMATION (RT): PRIMARY RESULTS FROM THE EPCORE CLL-1 TRIAL. University of Southern Denmark Research Portal (University of Southern Denmark). 1 indexed citations
2.
Karimi, Yasmin, Pau Abrisqueta, Sven de Vos, et al.. (2024). Epcoritamab + R-DHAX/C in transplant-eligible patients (pts) with high-risk relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).. Journal of Clinical Oncology. 42(16_suppl). 7032–7032. 7 indexed citations
3.
Falchi, Lorenzo, Joost S.P. Vermaat, Gerardo Musuraca, et al.. (2024). IBCL-278 Epcoritamab With Rituximab + Lenalidomide (R2) in Previously Untreated (1L) Follicular Lymphoma (FL) and Epcoritamab Maintenance Therapy in FL: EPCORE NHL-2 Arms 6 and 7. Clinical Lymphoma Myeloma & Leukemia. 24. S496–S497. 1 indexed citations
4.
Burger, Jan A., Paul M. Barr, Tadeusz Robak, et al.. (2024). CLL-076 Final Analysis of the RESONATE-2 Study: up to 10 Years of Follow-Up of First-Line Ibrutinib Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 24. S342–S343. 4 indexed citations
5.
Kater, Arnon P., Ann Janssens, Herbert Eradat, et al.. (2024). Epcoritamab Induces Deep Responses in Patients With Richter Transformation (RT): Primary Results From the EPCORE CLL-1 Trial. Clinical Lymphoma Myeloma & Leukemia. 24. S181–S181. 2 indexed citations
6.
Morschhauser, Franck, Carmelo Carlo‐Stella, Michael Dickinson, et al.. (2021). Glofitamab As Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients (pts) with Multiple Relapsed or Refractory (R/R) Follicular Lymphoma (FL). Blood. 138(Supplement 1). 128–128. 20 indexed citations
7.
Aftimos, Philippe, Christian Rolfo, Sylvie Rottey, et al.. (2017). Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies. Clinical Cancer Research. 23(21). 6411–6420. 47 indexed citations
8.
Offner, Fritz, Olga Samoilova, Evgenii A. Osmanov, et al.. (2015). Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL. Blood. 126(16). 1893–1901. 98 indexed citations
9.
Hansson, Markus, Peter Gimsing, Ashraf Badros, et al.. (2015). A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma. Clinical Cancer Research. 21(12). 2730–2736. 42 indexed citations
10.
Morgan, Gareth J., Antonio Palumbo, Sujith Dhanasiri, et al.. (2014). Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM ‐003 trial for pomalidomide plus low‐dose dexamethasone. British Journal of Haematology. 168(6). 820–823. 14 indexed citations
11.
Morgan, Gillian, Jesús F. San Miguel, Sujith Dhanasiri, et al.. (2014). Overall survival of patients with relapsed and refractory multiple myeloma: adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone vs. high-dose dexamethasone. Ghent University Academic Bibliography (Ghent University). 1 indexed citations
12.
13.
14.
Morschhauser, Franck, J.F. Seymour, Pierre Feugier, et al.. (2011). Impact of induction chemotherapy regimen on response, safety and outcome in the PRIMA study. Ghent University Academic Bibliography (Ghent University). 12 indexed citations
15.
Bouteloup, Marie, John Seymour, Patrick Feugier, et al.. (2011). Pattern of infections observed during the maintenance phase in the PRIMA study. Ghent University Academic Bibliography (Ghent University). 1 indexed citations
16.
Philippé, Jan, et al.. (2004). Correlation of ZAP-70 analysed by flow cytometry with IgVH mutational status in B-CLL. Ghent University Academic Bibliography (Ghent University). 1 indexed citations
17.
Marcus, Robert, Kevin Imrie, Andrew Belch, et al.. (2003). An international multi-centre, randomized, open-label, phase III trial comparing rituximab added to CVP chemotherapy to CVP chemotherapy alone in untreated stage III/IV follicular non-Hodgkins lymphoma.. Ghent University Academic Bibliography (Ghent University). 34 indexed citations
18.
Offner, Fritz, Tessa Kerre, Magda De Smedt, & Jean Plum. (1999). Bone marrow CD34+ cells generate fewer T cells in vitro with increasing age and following chemotherapy. British Journal of Haematology. 104(4). 801–808. 38 indexed citations
19.
Offner, Fritz, Gary Schoch, Lloyd D. Fisher, & Patrick Martin. (1994). MORTALITY HAZARD AS RELATED TO THE DURATION OF NEUTROPENIA AFTER MARROW TRANSPLANTATION. Ghent University Academic Bibliography (Ghent University). 2 indexed citations
20.
Sullivan, KM, Fritz Offner, Manfred Herold, et al.. (1994). RELATIONSHIP OF SERUM CYTOKINES (TNF-ALPHA, IL-1-BETA, IFN-GAMMA AND INFLAMMATION MARKERS (NEOPTERIN, BETA-2-MICROGLOBULIN, C-REACTIVE PROTEIN) TO TRANSPLANT-RELATED COMPLICATIONS AND IMMUNOGLOBULIN PROPHYLAXIS FOLLOWING ALLOGENEIC MARROW TRANSPLANTATION. Ghent University Academic Bibliography (Ghent University). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anders Österborg Breakdown of academic impact, for papers by Diane F. Jelinek Breakdown of academic impact, for papers by Adrian C. Newland Breakdown of academic impact, for papers by W. Hunstein Breakdown of academic impact, for papers by Andrew D. Clouston Breakdown of academic impact, for papers by Christian Récher Breakdown of academic impact, for papers by Norbert Ifrah Breakdown of academic impact, for papers by Timothy G. Call Breakdown of academic impact, for papers by Tsutomu Nobori Breakdown of academic impact, for papers by Lothar Bergmann
Rankless by CCL
2026